Redsenol, an innovative leader in ginseng and ginsenosides research and application, is thrilled to announce that the Redsenol Team presented groundbreaking research on the antitumor effects of rare ginsenosides and their potential in reducing cancer-related fatigue at the 2023 Canadian Cancer Research Conference (CCRC 2023).
The CCRC is the premier event for the Canadian cancer research community, bringing together researchers, trainees, clinicians, decision-makers, and patients to share the latest developments in the field. This year’s conference featured a diverse range of topics, making it an ideal platform for the Redsenol Team to showcase their cutting-edge work.
During the conference, the Redsenol Team unveiled the findings from their preclinical and clinical studies, which shed light on the remarkable antitumor effects of rare ginsenosides. Their research poster garnered significant interest from attendees, including esteemed professors from renowned institutions such as Ottawa University.
Currently, Redsenol is spearheading a clinical study to evaluate the safety and efficacy of their groundbreaking product, Redsenol-1 Plus, in alleviating cancer-related fatigue among adult patients who have undergone cancer treatment. Distinguished by its superior bioactivity and absorbability, Redsenol-1 Plus is a ginseng supplement enriched with rare ginsenoside monomers Rg3(R, S), Rh1(S, R), Rh2(R, S), Rk1, Rk3, Rg5, Rh3, Rh4, Rk2, aPPD(S, R), and aPPT(S, R). These monomers possess exceptional potency, surpassing that of common Panax or Korean red ginseng extracts.
This ground-breaking clinical trial has the potential to provide a much-needed solution for cancer-related fatigue, a debilitating symptom that affects countless individuals. The Redsenol Team is dedicated to advancing the field of cancer research and improving the lives of cancer patients worldwide.
“We are proud to be part of this prestigious conference. The opportunity to share our latest research at CCRC 2023, where groundbreaking cancer research is being discussed, is truly exciting and inspiring,” said Dr. Peihua Yu, CEO of Redsenol.
Redsenol’s commitment to innovative research and their mission to make a positive impact in cancer treatment and care is evident through their significant contributions to the growing body of knowledge in ginsenoside research. With their groundbreaking findings, the future of cancer treatment looks brighter than ever.
